Janssen Search
Search results
Investigational Ebola Vaccine in Sierra Leone
Maximizing the Impact of our Awareness and Development Efforts for an Investigational Ebola Vaccine in Sierra Leone The road to the EBOVAC-Salone clinic in Kambia, Sierra Leone The clinic, in Kambia, Sierra Leone, where the EBOVAC-Salone trial took place. ...
RYBREVANT®▼ (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
Jun 28, 2024 Approval is supported by the Phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease progression or death by 60 percent compared to chemotherapy alone 1 BEERSE, BELGIUM (28 June 2024) – ...
David Tripi
David Tripi is Global Head of Operations at Janssen Healthcare Innovation where he is part of a multi-disciplinary group working toward the goal of propelling the company to become the leader in the healthcare solution business. Prior to the launch of the ...
James F. List, M.D., Ph.D.
JAMES F. LIST, M.D., PH.D. GLOBAL THERAPEUTIC AREA HEAD CARDIOVASCULAR & METABOLISM James F. List, M.D., Ph.D., is the Global Therapeutic Area Head of Cardiovascular & Metabolism (CVM), leading a global team focused on creating new solutions for ...
James List, M.D., Ph.D.
JAMES LIST, M.D., Ph.D. GLOBAL THERAPEUTIC AREA HEAD CARDIOVASCULAR & METABOLISM James F. List, M.D., Ph.D. is the Global Therapeutic Area Head of Cardiovascular & Metabolism (CVM), leading a global team focused on creating new solutions for ...
Our Partnerships
Our Partnerships Partnerships are central to all that we do. Beyond our research and development (R&D) partnerships, we recognize the importance of building multi-sector alliances to address critical health needs. We are committed to working across ...
Respiratory Infections
Respiratory Infections Article Type: Infectious Diseases & Vaccines By focusing on vulnerable populations, we aim to improve health for everyone across the globe. At Janssen, we have a deep heritage of caring for those affected by respiratory ...
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
May 16, 2024 Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD) Includes bispecific antibodies targeting proven disease pathways and offers the potential ...
Johnson & Johnson Neuroscience R&D Newsroom
OUR COMMITMENT TO NEUROPSYCHIATRIC, NEURODEGENERATIVE DISEASES AND NEUROSCIENCE AUTOANTIBODY DISEASES Thank you for visiting the Johnson & Johnson Neuroscience R&D Newsroom! Below, please find our meeting news, social feeds, and more information ...
Marco Mohwinckel
Marco Mohwinckel is Global Head of Integrated Care Businesses at Janssen Healthcare Innovation. Prior to taking on this role, Marco was heading up the Neuroscience Business Unit and was a member of the United Kingdom Management Committee of Janssen ...